COMBINATION OF DEXTROMETHORPHAN AND BUPROPION FOR TREATING DEPRESSION
Disclosed herein are methods of treating neurological or psychiatric diseases or disorders, such as depression, using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.
1 . A method of treating major depressive disorder, comprising: selecting a human patient for not having anorexia nervosa, and selecting the human patient for experiencing major depressive disorder, and administering, twice a day, a combination of: 1) 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the dextromethorphan free base, and 2) 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the bupropion free base.
2 . The method of claim 1 , wherein the combination comprises 45 mg of dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride.
3 . The method of claim 2 , wherein dextromethorphan hydrobromide is in an immediate-release formulation.
4 . The method of claim 3 , wherein bupropion hydrochloride is in an extended-release formulation.
5 . The method of claim 1 , wherein the combination is administered in a tablet.
6 . The method of claim 5 , further comprising administering one tablet daily to the human patient for three days prior to administering one tablet twice daily to the human patient.
7 . The method of claim 6 , wherein the combination comprises 45 mg of dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride.
8 . The method of claim 7 , wherein dextromethorphan hydrobromide is in an immediate-release formulation.
9 . The method of claim 8 , wherein bupropion hydrochloride is in an extended-release formulation.
10 . The method of claim 1 , wherein the dextromethorphan contributes to the antidepressant properties of the combination comprising 45 mg of dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride.
11 . The method of claim 1 , wherein the combination is administered twice daily for at least 6 weeks.
12 . The method of claim 1 , wherein the combination is administered twice daily for at least 6 months.
13 . The method of claim 1 , wherein the combination is administered twice daily for at least 12 months.
14 . The method of claim 1 , wherein the combination is in a tablet further comprising microcrystalline cellulose.
15 . The method of claim 1 , wherein the combination is in a tablet further comprising magnesium stearate.
16 . The method of claim 1 , wherein the human patient meets the DSM-5 criteria for major depressive disorder.